EPARELLA GMBH

Their core work

Eparella GmbH is an Austrian biotech SME specializing in microalgae-based product development, bridging the gap between algae cultivation science and commercial applications in cosmetics and functional nutrition. Their work spans the full value chain: from cultivating and extracting bioactive compounds from algae to characterizing those compounds using multi-omics tools — genomics, transcriptomics, proteomics, and enzymomics. They develop finished products such as UV sunscreens, skin-care actives, and protein-rich nutraceutical ingredients derived from microalgae. They also apply molecular techniques for species identification and product authentication, which is increasingly important for quality assurance in the booming algae-ingredient market.

What they specialise in

How they've shifted over time

Eparella's two projects are close in time (2017–2023), but there is a clear shift in emphasis. VALUEMAG (2017–2020) focused upstream — on cultivation systems and extraction techniques, treating algae primarily as a biomass and process engineering challenge. AlgaeCeuticals (2018–2023) moved decisively downstream: it is about characterizing specific bioactive compounds at the molecular level, formulating finished cosmetic and nutritional products, and ensuring authenticity through species-level identification. The trajectory points away from generic biomass processing toward high-value, characterized ingredients with defined regulatory and commercial profiles — a more defensible and margin-rich market position.

Eparella is moving toward premium, science-backed algae ingredients for cosmetics and nutrition markets — organizations building consortia around bio-based personal care, functional food, or algae biorefinery would find them a well-positioned specialist partner.

How they like to work

Eparella has participated exclusively as a consortium partner — never as project coordinator — across both H2020 projects. Despite this supporting role, their network footprint is unusually broad for a two-project SME: 21 unique partners across 12 countries, suggesting they were embedded in large, multi-partner consortia rather than small bilateral projects. This pattern is consistent with a specialist contributor that brings niche technical capabilities (omics, algae formulation) which larger consortia need but cannot source internally.

Eparella has built connections with 21 distinct consortium partners spanning 12 countries through just two projects, indicating participation in large international consortia (BBI and MSCA-RISE programs both tend to involve broad multi-country partnerships). Their European reach is genuine, not superficial.

What sets them apart

Eparella occupies a rare niche among Austrian SMEs: they combine hands-on microalgae processing expertise with molecular-level omics characterization — capabilities that are usually found separately in either industrial biotech firms or university research groups. This dual competence makes them valuable both for upstream R&D consortia needing analytical depth and for downstream product development projects needing formulation and authentication know-how. For a consortium looking to bridge algae science and market-ready ingredients, Eparella provides that translation layer without the overhead of a large institution.

Highlights from their portfolio

• VALUEMAG
  The largest funding award (€300,000) and the project that established their algae cultivation and extraction credentials within the EU Bioeconomy funding landscape.
• AlgaeCeuticals
  A MSCA-RISE project demonstrating international research staff exchange, and the project that introduced their omics and product authentication capabilities — the more technically distinctive of the two.